Quental Cristiane, de Abreu Jussanã Cristina, Bomtempo José Vitor, Gadelha Carlos Augusto Grabois
Escola Nacional de Saúde Pública Sérgio Arouca, Fiocruz, Manguinhos, 21041-210 Rio de Janeiro RJ.
Cien Saude Colet. 2008 Apr;13 Suppl:619-28. doi: 10.1590/s1413-81232008000700011.
This paper echoes recent works of Abrasco, Gadelha and Guimarães emphasizing the need for a better integration between health policies and industrial development and innovation policies as the only way to keep the economic benefits generated by health expenditures in the country instead of letting them escape through imports and threaten the continuity of the social policy by growing trade deficits. Although presenting the generic drug policy as a successful case in integrating social policies aimed at a better access to quality drugs for the population with economic policies aimed at industrial development, this paper discusses the impacts and limitations of the referred policy in a dialog with Abreu's analysis of industrial competitiveness in the Brazilian generics industry.
本文呼应了阿卜拉斯科、加德利亚和吉马良斯最近的著作，强调卫生政策与产业发展及创新政策之间需要更好地整合，这是将卫生支出在国内产生的经济效益留住的唯一途径，而不是让这些效益通过进口流失，并因贸易逆差不断扩大而威胁社会政策的连续性。尽管本文将仿制药政策作为将旨在让民众更好地获得优质药品的社会政策与旨在促进产业发展的经济政策相结合的成功案例进行了阐述，但本文在与阿布雷乌对巴西仿制药行业产业竞争力的分析的对话中，讨论了上述政策的影响和局限性。
